non-compartmental model for intravascular constant infusion (BioProof Inc)
90
Structured Review
BioProof Inc
non-compartmental model for intravascular constant infusion
Non Compartmental Model For Intravascular Constant Infusion, supplied by BioProof Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/non-compartmental+model+for+intravascular+constant+infusion/non+compartmental+model+for+intravascular+constant+infusion/pm23090290-49-16-24
Average 90 stars, based on 1 article reviews
Non Compartmental Model For Intravascular Constant Infusion, supplied by BioProof Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/non-compartmental+model+for+intravascular+constant+infusion/non+compartmental+model+for+intravascular+constant+infusion/pm23090290-49-16-24
Average 90 stars, based on 1 article reviews
non-compartmental model for intravascular constant infusion - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
other:Article Title: Clinical safety and pharmacological profile of the HLA-DR antibody 1D09C3 in patients with B cell chronic lymphocytic leukemia and lymphoma: results from a phase I study. Article Snippet: 1D09C3 is a human monoclonal IgG4-type antibody against human leukocyte antigen-DR (HLA-DR) which has demonstrated pro-apoptotic activity against lymphoid tumors in vitro and in vivo.. We report results from a phase I dose-escalation study which aimed to identify tolerated dosing, and the pharmacokinetic and pharmacodynamic profile of 1D09C3.. Fourteen patients with relapsed/refractory B cell type leukemia/lymphoma were treated and followed after up to 4 weekly infusions of 1D09C3, administered in 6 dose levels at 0.25–8 mg/kg/ day. |